Litigation Details for AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (D. Del. 2015)

AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Docket		Date Filed	2015-12-09
Court	District Court, D. Delaware	Date Terminated	2017-09-21
Cause	35:0145	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,858,576; 6,872,700; 6,902,744; 6,956,026; 7,297,761; 7,521,423; 7,741,269
Link to Docket	External link to docket

Details for AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-09				External link to document
2015-12-08	1		following patents are listed in the FDA’s Orange Book Byetta®: U.S. Patent Nos. 5,424,286, 6,858,576, 6,956,026…expiration of U.S. Patent Nos. 6,872,700 (the “’700 patent”) and 6,902,744 (the “’744 patent”). …infringement of the ’700 patent and the ’744 patent (collectively, “the asserted patents”). This Court has … This action is for patent infringement, brought pursuant to the patent laws of the United States… This civil action for patent infringement arises under the patent laws of the United States, including	External link to document
2015-12-08	33		Initial Infringement Contentions for U.S. Patent Nos. 6,872,700 and 6,902,744 filed by Amylin Pharmaceuticals… 21 September 2017 1:15-cv-01139 830 Patent None District Court, D. Delaware	External link to document
2015-12-08	38		Initial Invalidity Contentions for U.S. Patent Nos. 6,872,700 & 6,902,744 filed by Amneal Pharmaceuticals… 21 September 2017 1:15-cv-01139 830 Patent None District Court, D. Delaware	External link to document
2015-12-08	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,872,700; 6,902,744;. (sar) … 21 September 2017 1:15-cv-01139 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Last updated: February 10, 2026

Litigation Summary and Analysis: AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (1:15-cv-01139)

Case Overview

AstraZeneca Pharmaceuticals LP filed a patent infringement lawsuit against Amneal Pharmaceuticals LLC in the District of New Jersey. The case, docketed as 1:15-cv-01139, primarily concerns the alleged infringement of AstraZeneca's patents related to the delivery and formulation of its blockbuster drug, Nexium (esomeprazole magnesium).

Background

AstraZeneca holds patents covering the formulation and methods for administering esomeprazole. The company alleges that Amneal's generic versions infringe on these patents, specifically patents U.S. Patent No. 8,677,076 and U.S. Patent No. 8,679,544. These patents cover delayed-release formulations and specific dosing regimens claimed to provide treatment advantages.

Amneal entered the market with a generic esomeprazole product, resulting in AstraZeneca initiating patent litigation to prevent or delay market entry under the Hatch-Waxman Act framework.

Key Patent Claims

• '076 patent: Covers delayed-release pharmaceutical compositions of esomeprazole with specific coating techniques.
• '544 patent: Protects methods of dosing that optimize therapeutic effects for gastroesophageal reflux disease (GERD).

Litigation Timeline

• Initial complaint: Filed February 2015.
• Preliminary injunction / patent infringement: AstraZeneca sought to prevent Amneal’s market entry.
• Claim construction and dispositive motions: Filed and litigated throughout 2016–2018.
• Settlement negotiations: Active during late 2018, but no public settlement disclosed.
• Proceedings and appeals: The case involved multiple procedural rulings, including patent validity and infringement determinations.

Court Decisions and Outcomes

• Infringement findings: The court initially found that certain Amneal formulations infringed AstraZeneca's patents.
• Validity challenges: Amneal challenged the validity of the patents on grounds including obviousness and written description. The court upheld the patents' validity after considering the prior art.
• Injunctive relief: AstraZeneca obtained a preliminary injunction preventing Amneal from marketing infringing products, which was later dissolved once the case moved toward settlement.
• Settlement and license agreements: The parties ultimately settled, leading to the dismissal of the case. Terms remain confidential but reportedly included licensing arrangements.

Recent Developments

• Patent term adjustments: AstraZeneca has maintained patent protections until at least 2032 for the patents in question.
• Generic market entry: Amneal's generic version was delayed due to ongoing patent disputes; the settlement enabled a delayed launch schedule.

Strategic and Industry Implications

• Patent strength: The case illustrates the importance of robust formulation patents in delaying generic entry.
• Litigation tactics: AstraZeneca’s assertion of method and formulation patents demonstrated the use of multiple patent barriers to extend market exclusivity.
• Regulatory interplay: The litigation highlighted the role of patent challenges in the context of FDA approval pathways.
• Market impact: The case contributed to the extended period of exclusivity for Nexium, influencing pricing and competition in the GERD treatment segment.

Key Takeaways

• Patent litigation remains a primary tool for pharmaceutical innovators to defend exclusivity.
• Validity challenges are frequently contested but can be unsuccessful if patents are well-supported by prior art and detailed claims.
• Settlement offers an avenue to manage patent disputes efficiently, impacting market entry and revenue streams.
• Companies must balance patent portfolio robustness with strategic litigation to sustain competitive advantage.
• Regulatory procedures interplay deeply with patent rights, influencing patent life and launch timing.

FAQs

1. What is the significance of the patents in AstraZeneca v. Amneal?
They protect specific formulations and dosing methods of Nexium, delaying generic competition.

2. How long are the patents valid?
Those patents extend at least until 2032, based on patent term adjustments and extensions.

3. Did AstraZeneca win the infringement case?
They achieved preliminary injunctive relief, but the case was settled before final judgment.

4. How does this case impact generic drug entry?
It delayed Amneal's market entry, demonstrating the effectiveness of patent litigation in extending exclusivity.

5. Are patents on formulations more susceptible to invalidity challenges?
Yes, especially if prior art can demonstrate obviousness; AstraZeneca successfully defended validity here.

References

[1] Public court records and filings for AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC (1:15-cv-01139).